Literature DB >> 7304570

Duration of serum antitoxin response following Vibrio cholerae infection in North Americans: relevance for seroepidemiology.

M M Levine, C R Young, T P Hughes, S O'Donnell, R E Black, M L Clements, R Robins-Browne, Y L Lim.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1981        PMID： 7304570     DOI： 10.1093/oxfordjournals.aje.a113201

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN： 0002-9262            Impact factor:   4.897


× No keyword cloud information.
  9 in total

1.  Cholera toxin adjuvant promotes long-term immunological memory in the gut mucosa to unrelated immunogens after oral immunization.

Authors:  M Vajdy; N Y Lycke
Journal:  Immunology       Date:  1992-03       Impact factor: 7.397

Review 2.  Cholera.

Authors:  J B Kaper; J G Morris; M M Levine
Journal:  Clin Microbiol Rev       Date:  1995-01       Impact factor: 26.132

Review 3.  New knowledge on pathogenesis of bacterial enteric infections as applied to vaccine development.

Authors:  M M Levine; J B Kaper; R E Black; M L Clements
Journal:  Microbiol Rev       Date:  1983-12

4.  Randomized, double-blind, placebo-controlled, multicentered trial of the efficacy of a single dose of live oral cholera vaccine CVD 103-HgR in preventing cholera following challenge with Vibrio cholerae O1 El tor inaba three months after vaccination.

Authors:  C O Tacket; M B Cohen; S S Wasserman; G Losonsky; S Livio; K Kotloff; R Edelman; J B Kaper; S J Cryz; R A Giannella; G Schiff; M M Levine
Journal:  Infect Immun       Date:  1999-12       Impact factor: 3.441

Review 5.  Current perspectives on the epidemiology and pathogenesis of clinically significant Vibrio spp.

Authors:  J M Janda; C Powers; R G Bryant; S L Abbott
Journal:  Clin Microbiol Rev       Date:  1988-07       Impact factor: 26.132

6.  Randomized, controlled human challenge study of the safety, immunogenicity, and protective efficacy of a single dose of Peru-15, a live attenuated oral cholera vaccine.

Authors:  Mitchell B Cohen; Ralph A Giannella; Judy Bean; David N Taylor; Susan Parker; Amy Hoeper; Stephen Wowk; Jennifer Hawkins; Sims K Kochi; Gilbert Schiff; Kevin P Killeen
Journal:  Infect Immun       Date:  2002-04       Impact factor: 3.441

7.  Optimal allocation of the limited oral cholera vaccine supply between endemic and epidemic settings.

Authors:  Sean M Moore; Justin Lessler
Journal:  J R Soc Interface       Date:  2015-10-06       Impact factor: 4.118

8.  Enzyme-linked immunosorbent assay to measure antibodies to purified heat-labile enterotoxins from human and porcine strains of Escherichia coli and to cholera toxin: application in serodiagnosis and seroepidemiology.

Authors:  M M Levine; C R Young; R E Black; Y Takeda; R A Finkelstein
Journal:  J Clin Microbiol       Date:  1985-02       Impact factor: 5.948

9.  Seroepidemiologic survey of epidemic cholera in Haiti to assess spectrum of illness and risk factors for severe disease.

Authors:  Brendan R Jackson; Deborah F Talkington; James M Pruckler; M D Bernadette Fouché; Elsie Lafosse; Benjamin Nygren; Gerardo A Gómez; Georges A Dahourou; W Roodly Archer; Amanda B Payne; W Craig Hooper; Jordan W Tappero; Gordana Derado; Roc Magloire; Peter Gerner-Smidt; Nicole Freeman; Jacques Boncy; Eric D Mintz
Journal:  Am J Trop Med Hyg       Date:  2013-10       Impact factor: 2.345
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.